ProfileGDS5678 / 1439924_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 52% 51% 50% 50% 53% 56% 51% 50% 50% 52% 50% 53% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3831854
GSM967853U87-EV human glioblastoma xenograft - Control 23.2533452
GSM967854U87-EV human glioblastoma xenograft - Control 33.2436851
GSM967855U87-EV human glioblastoma xenograft - Control 43.1428650
GSM967856U87-EV human glioblastoma xenograft - Control 53.152950
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4118753
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5119956
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2353651
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1797750
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1915850
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2478652
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1748950
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.305853
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2445752